Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

15 avr. 2026 16h01 HE | Source: Traws Pharma, Inc.

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity, Ratutrelvir topline Phase 2a data show...
15 avr. 2026 08h15 HE | Source: Traws Pharma, Inc.

Traws Pharma Announces Up to $60 Million Private Placement Financing

Financing led by Sirenia Capital Management LP advances Traws Pharma's influenza program through a human challenge trial for tivoxavir marboxil in the United Kingdom NEWTOWN, Pa., April 15, 2026 ...
19 févr. 2026 07h30 HE | Source: Traws Pharma, Inc.

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution;...
26 janv. 2026 08h30 HE | Source: Traws Pharma, Inc.

Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution;...
13 janv. 2026 07h00 HE | Source: Traws Pharma, Inc.

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic...